Abeona Therapeutics’ (ABEO) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a report issued on Thursday morning. HC Wainwright currently has a $17.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also weighed in on the stock. FBR & Co reaffirmed a positive rating on shares of Abeona Therapeutics in a research note on Wednesday. Maxim Group set a $14.00 price objective on shares of Abeona Therapeutics and gave the stock a buy rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed a buy rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research note on Friday, September 30th. Finally, Zacks Investment Research lowered shares of Abeona Therapeutics from a hold rating to a sell rating in a research note on Monday, September 12th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $14.50.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded up 2.59% during mid-day trading on Thursday, hitting $6.73. 501,028 shares of the stock were exchanged. The stock’s market cap is $225.76 million. The stock’s 50 day moving average is $5.15 and its 200-day moving average is $3.38. Abeona Therapeutics has a 12 month low of $2.05 and a 12 month high of $7.19.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. On average, analysts anticipate that Abeona Therapeutics will post ($0.73) EPS for the current year.
In related news, Director Todd Wider acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, September 20th. The shares were purchased at an average price of $5.48 per share, for a total transaction of $27,400.00. Following the completion of the acquisition, the director now directly owns 75,000 shares in the company, valued at approximately $411,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 13.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Royce & Associates LP increased its position in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares during the period. Sabby Management LLC increased its position in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the period. BlackRock Fund Advisors increased its position in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares during the period. Finally, Geode Capital Management LLC increased its position in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the period. Hedge funds and other institutional investors own 19.95% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.